Peer-review articles

  • Wacker MG (2017); Challenges in the drug release testing of next-generation nanomedicines - What do we know?, Materials Today Proceedings (Submitted to journal)
  • Janas C, Mast MP, Kirsamer L, Angioni C, Gao F, Mäntele W, Dressman J, Wacker MG (2017); The dispersion releaser technology is an effective method for testing the drug release from nanosized carriers, Eur. J. Pharm. Biopharm. 115:73-83.
  • Beyer S, Xie L, Schmidt M, de Bruin N, Ashtikar M, Rüschenbaum S, Lange CM, Vogel V, Mäntele W, Parnham MJ, Wacker MG; Optimizing novel implant formulations for the prolonged release of biopharmaceuticals using in vitro and in vivo imaging techniques, J. Control. Release, 10 (235):352-364.

  • Wacker MG, Proykova A, Santos GM (2016); Dealing with nanosafety around the globe – Regulation vs. Innovation, Int. J. Pharm. 509(1-2):95-106.
  • Janas C, Mostaphaoui Z, Schmiederer L, Bauer J, Wacker MG (2016); Novel polymeric micelles for drug delivery: Material characterization and formulation screening, Int. J. Pharm. 509(1-2)197-207.
  • Beyer S, Moosmann A, Kahnt AS, Ulshöfer T, Parnham MJ, Ferreirós N, Wacker MG (2015); Drug release and targeting: The versatility of polymethacrylate nanoparticles for peroral administration revealed by using an optimized in vitro-toolbox, Pharm. Res. 32(12):3986-3998.
  • Bergs JW, Wacker MG, Hehlgans S, Piiper A, Multhoff G, Rödel C,Rödel F (2015); The role of recent nanotechnology in enhancing the efficacy of radiation therapy, Biochim. Biophys. Acta 1856(1):130-143.
  • Villa Nova M, Janas C, Schmidt M, Ulshöfer T, Gräfe S, Schiffmann S, de Bruin N, Wiehe A, Albrecht V, Parnham MJ, Bruschi ML, Wacker MG (2015); Nanocarriers for photodynamic therapy - Rational formulation design and medium-scale manufacture, Int. J. Pharm. 491(1-2):250-260.
  • Xie L, Beyer S, Vogel V, Wacker MG, Mäntele W (2015); Assessing the Drug Release from Nanoparticles: Overcoming the Shortcomings of Dialysis by Using Novel Optical Techniques and a Mathematical Model, Int. J. Pharm. 488(1-2): 108-19
  • Beyer S, Xie L, Graefe S, Vogel V, Dietrich K, Wiehe A, Albrecht V, Maentele W, Wacker MG (2015); Bridging Laboratory and Large Scale Production: Preparation and In Vitro-Evaluation of Photosensitizer-Loaded Nanocarrier Devices for Targeted Drug Delivery, Pharm. Res. 32(5):1714-1726
  • Wacker MG, Altinok M, Urfels S, Bauer J (2014); Nanoencapsulation of superparamagnetic particles of iron oxide into human serum albumin nanoparticles, Beilstein J. Nanotechnol. 5:2259-66
  • Wacker MG; Hund-Rinke K, Creutzenberg O (2014); Quo vadis Nano? Nanomaterialien in der pharmazeutische Produktentwicklung, Pharm. Ind.7: 1134-1140
  • Wacker MG; Nanotherapeutics - Product development alo.ng the ‘nanomaterial’ discussion (2014), J. Pharm. Sci. 103(3):777-784
  • Wacker M (2013); Nanocarriers for intravenous injection – The long hard road to the market, Int. J. Pharm. 457(1):50-62.
  • Gaca S, Reichert S, Multhoff G, Wacker M, Hehlgans S, Botzler C,Gehrmann M, Rödel C, Kreuter J, Rödel F (2013); Targeting by cmHsp70.1-antibody coated and Survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells, J. Control. Release 172(1):201-206.
  • Hofmann B, Rödl CB, Fischer AS, Maier TJ, Michel AA, Hoffmann M, Rau O, Awwad K, Pellowska M, Wurglics M, Wacker M, Živković A, Fleming I, Schubert-Zsilavecz M, Stark H, Schneider G, Steinhilber D (2012); Molecular pharmacological profile of a novel thiazolinone-based direct and selective 5-lipoxygenase inhibitor, Br. J. Pharmacol. 165(7):2304-2313.
  • Wacker M, Zensi A, Kufleitner J, Ruff A, Schütz J, Stockburger T, Marstaller T, Vogel V (2011); A toolbox for the upscaling of ethanolic human serum albumin (HSA) desolvation, Int. J. Pharm. 414(1-2):225-232.
  • Löw K, Wacker M, Wagner S, Langer K, von Briesen H (2011); Targeted human serum albumin nanoparticles for specific uptake in EGFR-expressing colon carcinoma cells, Nanomedicine 7(4):454-463.
  • Preuss A, Hackbarth S, Wacker M, Knobloch T, Langer K, Röder B (2010); Comprehensive in vitro investigations on biodegradable photosensitizer-nanoparticle delivery systems, J. Control. Release 148(1):117-118.
  • Zheng SZ, Löw K, Wacker M, Wiehe A, Wagner S, Langer K, von Briesen H, Zou SQ (2010); Interaction and cytotoxicity of mTHPC and mTHPC complexes in Jurkat cells. Chin. J. Exp. Surg. 27:13-22.
  • Chen K, Wacker M, Hackbarth S, Ludwig C, Langer K, Roeder B (2010); Photophysical evaluation of mTHPC-loaded HSA nanoparticles as novel PDT delivery systems, J. Photochem. Photobiol. B 101(3):340-347.
  • Wacker M, Chen K, Preuss A, Possemeyer K, Roeder B, Langer K (2010); Photosensitizer loaded HSA nanoparticles I: Preparation and photophysical properties, Int. J. Pharm. 93(1-2):253-262.
  • Chen K, Preuss A, Hackbarth S, Wacker M, Langer K, Roeder B (2009); Novel photosensitizer-protein nanoparticles for photodynamic therapy: photophysical characterization and in vitro investigations, J. Photochem. Photobiol. B 96(1):66-74.

 

Patents and patent applications

  • Wacker MG, Beyer S, Xie L, Vogel V, Maentele W, Parnham MJ; Composition comprising biocompatible and biodegradable polymer, nanocarriers and a drug and methods of making and using the same, European Patent Application (FH13533EP)
  • Wacker MG, Janas C; Adapter für die Freisetzung disperser Arzneizubereitungen (Dispersion Releaser), German Patent 2015 (DE102013015522 A1) / PCT application 2014 (PCT/EP2014/002523)
  • Langer K, Wacker M, Röder B, Preuss A, Albrecht V, Gräfe S, Wiehe A, von Briesen H, Löw K, Wagner S; Nanoparticle carrier systems based on human serum albumin for photodynamic therapy (US 2011/0142948 A1)

 

Abstracts and presentations

 

  • Wacker MG (2017); Challenges in the drug release testing of next-generation nanomedicines, FIP/USP/AAPS workshop Nanomedicines - Technical and Regulatory Perspectives, Rockville, USA

  • Wacker MG (2016); Designing nanocarriers for drug delivery, NRW-Nanokonferenz, Münster, Germany

  • Wacker MG (2016); Challenges in the drug release testing of next generation nanomedicines, DECHEMA platform NanoBioMedizin, Frankfurt, Germany

  • Nothnagel L, Thurn M, Wacker MG (2016); DoE-based development and in vitro drug release testing of TMP-001 loaded nanocarriers, GPEN Annual Meeting 2016, Lawrence, Kansas, USA

  • Jablonka L, Thurn M, Wacker MG (2016); In vitro drug release testing of liposomal temoporfin formulations with the dispersion releaser technology, GPEN Annual Meeting 2016, Lawrence, Kansas, USA

  • Wacker MG (2016), ANVISA discussion group on "Nanomedicines", Brasilia, Brazil

  • Wacker MG (2016), Designing Nanomedicines for the Market, Drug Delivery & Formulation Summit, Berlin, Germany

  • Wacker MG (2016), Assessing the drug release from nanocarriers: when, why and how?, Pharma Test Indonesia Workshop, Jakarta, Indonesia

  • Wacker MG (2016), Assessing the drug release from nanocarriers: when, why and how?, Matrix Analytical Technologies Workshop, Kuala Lumpur, Malaysia

  • Wacker MG (2016), Assessing the drug release from nanocarriers: when, why and how?, 1st LOSAN Drug Delivery Conference on Formulation Technologies, Frankfurt, Germany

  • Wacker MG (2015), Die neue Nanomedizin - Von der Idee zum Produkt, Treffen der Deutschen Plattform NanoBioMedizin, Frankfurt, Germany

  • Wacker MG (2015), Nanocarrier for Drug Delivery - Rational Formulation Design, University of Namibia, Windhoek, Namibia (Invited presentation)

  • Wacker MG (2015), Nanocarriers for Drug Delivery - Rational Formulation Design, 1st International Symposium on Drug Delivery Systems (SISLiF), Maringá, Brazil

  • Wacker MG (2015), Pharmazeutische Technologie "Quo Vadis Nano?", IHK-Event / Zu Gast beim LOEWE-Zentrum Translationale Medizin und Pharmakologie, Frankfurt, Germany

  • Wacker MG (2015), Parenteralia, Ophthalmika und perorale Suspensionen - Stabilität, Teilchengrößenwachstum und Freisetzung, FAH Workshop - Pharmaproduktion und Partikel, Bonn, Germany

  • Wacker MG (2015), Nanocarriers for Cancer Therapy - Rational Formulation Design, Evonik-LOSAN Workshop, Darmstadt, Germany

  • Wacker MG (2015), Nanocarriers for Drug Delivery - Rational Formulation Design, Drug Delivery and Formulation Global Summit, Düsseldorf, Germany

  • Wacker MG (2014), Rational Formulation Design - Nanomedizin mal anders!, DPhG Seminar, Freiburg, Germany

  • Beyer S, Wacker MG (2014), Nanocarriers for Drug Delivery - Rational Formulation Design, International Conference on Advances and Progress in Human Health Management and Healthcare Reforms (ADICON), Sagar, India

  • Janas C, Dressman JB, Wacker MG (2014), The Dispersion Releaser: An Optimal Tool for Selection of Colloidal Dosage Forms, Globalization of Pharmaceutics Education Network (GPEN) Nineth Meeting, Helsinki, Finland

  • Beyer S, Gräfe S, Albrecht V, Wacker MG (2014), Accepting the Challenge of Scale-up - A New Approach for the Targeted Treatment of Colon Cancer based on Nanoparticles overcomes the Limitations of Batch Size, Controlled Release Socienty Annual Meeting, Chicago, USA

  • Wacker MG (2014), Rational Formulation Design - Nanomedizin mal anders!, Neue Potentiale für die Nanotechnologie in der Medizin, Darmstadt, Germany

  • Wacker MG, Parnham MJ (2014), Achieving a Good Working Relationship with an Academic Research Organization, Drug Delivery & Formulation Americas Summit, San Diego, USA

  • Janas C, Dressman JB, Wacker M (2013); Innovative Nanocarrier Systems for the Delivery of Temoporfin: In vitro selection and formulation refinement, American Association of Pharmaceutical Scientists (AAPS) Annual meeting and exposition, San Antonio, USA

  • Wacker M (2013); Nanocarrier - Entwicklung und Optimierung innovativer Arzneistoffträger, PharmaForum Hessen 2013, Mainz, Germany

  • Beyer S, Ferreirós Bouzas N, Kahnt AS, Wacker M (2013); Polymethacrylic acid-based nanoparticles for the peroral delivery of flurbiprofen – physicochemical properties and evaluation in cell culture models, 40th Annual Meeting and Exposition of the Controlled Release Society 2013, Honolulu, USA

  • Beyer S, Vogel V, Schlupp P, Engelmann V, Baumstümmler B, Türeli A, Wieland G, Wiehe A, Gräfe S, Albrecht V, Runkel F, Wacker M  (2013); Eudragit nanoparticles for photodynamic therapy: optimization of formulation design and manufacture, 40th Annual Meeting and Exposition of the Controlled Release Society 2013, Honolulu, USA

  • Wacker M (2013) Nanocarrier - Trends in Modern Formulation Development, Innovative Dosage Forms in Development and Production Workshop, Essen, Germany

  • Janas C, Wacker M (2012), Rational Design of Nanoparticle Dissolution Testing: The challenge of in vitro drug release, DPhG Doktorandentagung, Greifswald, Germany

  • Beyer S, Wacker M (2012), Eudragit nanoparticles - An advanced controlled release carrier system for non-steroidal anti-inflammatory drugs (NSAIDs), Pharma Forum Hessen 2012, Hanau, Germany

  • Beyer S, Dietrich K, Wacker M (2012), Manufacture of porphyrin-loaded Eudragit nanoparticles - A mucoadhesive drug delivery system. Controlled Release Society (CRS) German Chapter Annual Meeting, Würzburg, Germany

  • Dietrich K, Wacker M (2012), Manufacture of porphyrin-loaded Eudragit nanoparticles - A mucoadhesive drug delivery system. 8th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology 2012, Istanbul, Turkey

  • Wacker M (2011); Nanopartikel - Eine neue Alternative in der peroralen Arzneistoffformulierung, Pharmaforum 2011 Saarland, St. Ingbert, Germany

  • Wacker M, Ruff A, Schütz J, Vogel V (2011); Upscaling of ethanolic human serum albumin (HSA) desolvation. 38th Annual Meeting and Exposition of the Controlled Release Society 2011, National Harbor, USA

  • Wacker M, Ruff A, Schütz J, Vogel V (2011); Upscaling of ethanolic human serum albumin (HSA) desolvation. DPhG Doktorandentagung 2011, Heringsdorf, Germany

  • Wacker M, Ruff A, Schütz J, Vogel V (2011); Upscaling of ethanolic human serum albumin (HSA) desolvation. Controlled Release Society (CRS) German Chapter Annual Meeting, Jena, Germany

 

Awards & Sponsorships

  • Sponsorship of the National Counsel of Technological and Scientific Development (Brazil)
    CNPq program for visiting researchers
    (process no. 450547/2015-09)

 

  • European Eudragit Award for the Best Paper in 2014 (together with the first author) for the manuscript:

    Beyer S, Xie L, Graefe S, Vogel V, Dietrich K, Wiehe A, Albrecht V, Maentele W, Wacker MG, Bridging Laboratory and Large Scale Production: Preparation and In Vitro-Evaluation of Photosensitizer-Loaded Nanocarrier Devices for Targeted Drug Delivery, Pharm. Res. (32), 1714-1726

 

  • Galenus Supports 2011, Galenus-Stiftung, Austria
  • AAPS Poster Award 2010, AAPS, USA

 

Other publications and authorships

Contact information

 

Dr. Matthias G. Wacker

Goethe University
Institute of Pharmaceutical Technology

Max-von-Laue-Str. 9
D-60438 Frankfurt

 

Phone: +49 (0) 69 - 798 - 29691
Fax       +49 (0) 69 - 798 - 29694

Email: info [a] nanomedicines.de

Druckversion Druckversion | Sitemap
Nanosized drug delivery